THERAPY DOSSIER · th-209811ea162b

PprI protein from Deinococcus radiodurans, expressed and purified from Pichia pastoris

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27222438 ↗2016Reported benefit

The protein PprI provides protection against radiation injury in human and mouse cells.

MixedRadiationBALB/cMalen = 10 mice per group for the 30-day mortality study; 12 mice p…Intraperitoneal injection in mice; added to culture medium in vitro100 micrograms/kg in mice; 4 micrograms/mL in HUVEC cultureMice dosed 1 h before, 1 h after and 24 h after irradiation; HUVECs pretreated…

Model: Acute whole-body gamma irradiation from a cobalt-60 source at 6 Gy (30-day mortality) or 4 Gy (haematology, bone marrow clonogenic assay, organ histopathology and antioxidant assays) at 2 Gy/min; HUVECs irradiated at 2 or 4 Gy at 0.38 Gy/min

PprI reduced 30-day mortality after 6 Gy from 50% to 20%, improved white blood cell and lymphocyte counts on day 7 and platelet counts on days 7 and 14, increased bone marrow colony formation, limited histopathological damage to lung, liver, kidney and testis, and raised superoxide dismutase and ca…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…